Children's Oncology Group's 2023 blueprint for research: Bone tumors
Pediatric Blood & Cancer · 2023
DOI: 10.1002/pbc.30583 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2023. Verfasst von Damon R Reed und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Individualized Cancer Management, Moffitt Cancer Center, Tampa, Florida, USA. Hauptthemen laut MEDLINE: Bone Neoplasms, Sarcoma, Ewing, Osteosarcoma, Neuroectodermal Tumors, Primitive, Peripheral. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIH HHS, National Institutes of Health.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
The Children's Oncology Group (COG) Bone Tumor Committee is responsible for clinical trials and biological research on localized, metastatic, and recurrent osteosarcoma and Ewing sarcoma (EWS). Results of clinical trials in localized disease completed and published in the past 10 years have led to international standard‐of‐care chemotherapy for osteosarcoma and EWS. A recent focus on identifying disease subgroups has led to the identification of biological features associated with poor outcomes including the presence of circulating tumor DNA (ctDNA) at diagnosis, and specific genomic alterations—MYC amplification for osteosarcoma and STAG2 and TP53 mutation for EWS. Studies validating these potential biomarkers are under way. Clinical trials evaluating the addition of multitargeted kinase inhibitors, which are active in relapsed bone sarcomas, to standard chemotherapy are under way in osteosarcoma and planned in EWS. In addition, the Committee has data analyses and a clinical trial under way to evaluate approaches to local management of the primary tumor and metastatic sites. Given the rarity of bone sarcomas, we have prioritized international interactions and are in the process of forming an international data‐sharing consortium to facilitate refinement of risk stratification and study of rare disease subtypes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Individualized Cancer Management, Moffitt Cancer Center, Tampa, Florida, USA.
- Division of Oncology, Children's Hospital of Philadelphia Research Institute, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- Department of Oncology, Children's Hospital of Orange County, Orange, California, USA.
- Department of Sarcoma, Moffitt Cancer Center, Tampa, Florida, USA.
- Keck School of Medicine, University of Southern California and Children's Oncology Group, Monrovia, California, USA.
- Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.
ORCID-Profile: Jessica Davis, Steven G DuBois, Katherine A Janeway
Förderung
- NCI NIH HHS
- NIH HHS
- National Institutes of Health
Zitieren
APA
Reed, D. R., Grohar, P., Rubin, E., Binitie, O., Krailo, M., Davis, J., DuBois, S. G., & Janeway, K. A. (2023). Children's Oncology Group's 2023 blueprint for research: Bone tumors. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.30583
Vancouver
Reed DR, Grohar P, Rubin E, Binitie O, Krailo M, Davis J, et al. Children's Oncology Group's 2023 blueprint for research: Bone tumors. Pediatric Blood & Cancer. 2023. doi:10.1002/pbc.30583
BibTeX
@article{Reed2023,
author = {Reed, Damon R and Grohar, Patrick and Rubin, Elyssa and Binitie, Odion and Krailo, Mark and Davis, Jessica and DuBois, Steven G and Janeway, Katherine A},
title = {Children's Oncology Group's 2023 blueprint for research: Bone tumors},
journal = {Pediatric Blood & Cancer},
year = {2023},
doi = {10.1002/pbc.30583}
}
EUVIMED